Montelukast oral film - IntelGenx

Drug Profile

Montelukast oral film - IntelGenx

Alternative Names: INT 0043/2015; INT0043; Montelukast repurposed - IntelGenx

Latest Information Update: 24 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IntelGenx Corp.
  • Class Acetates; Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Mild cognitive impairment

Highest Development Phases

  • Phase I Alzheimer's disease; Mild cognitive impairment

Most Recent Events

  • 22 Aug 2016 Pharmacokinetics data from a phase I trial in Healthy volunteers released by IntelGenx
  • 22 Aug 2016 IntelGenx completes phase I trial in healthy volunteers
  • 27 Jul 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top